Published Date : Mar 06, 2017
ALBANY, New York, March 06, 2017 – MarketResearchReports.biz has announced the addition of a new report to its repository, titled “Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs And Protein Kinases Dominate Pipeline, With Most Promising First-In-Class Targets Demonstrating Potential Disease-Modifying Effects.” The report studies the statues of the market in its current scenario and based on an reports various factors that are expected to influence the demand in the near future, it estimates the future.
The report observes that Type 2 diabetes mellitus (T2DM) is a life-threatening chronic metabolic disorder, which is signified by high glucose levels in the blood (hyperglycemia) and causes several complications in the patients, including renal, cardiovascular, and neurodegenerative diseases. According to the report, in the past few decades, the prevalence of these diseases has escalated rapidly, owing to factors such as increasing obesity cases across the world. Noticing this rising healthcare issue, a number of players have invested to device new drugs and as a result, the competition has gone quite stiff in the recent past across different segments of therapy of the market. For instance, new drugs such as dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter 2 (SGLT-2) have been quite successful commercially and have now own a significant share of the market.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/903616
However, there still is vast population base with unmet needs for Type 2 diabetes mellitus, which is urging further investments on research and development of first-in-class drugs across various regions. The report finds that first-in-class products amount for a notable chunk of the market, and identifies several T2DM pipelines that may enter the market in the near future.
The report not only studies the competitive landscape, it also throws light on strong investment in first-in-class innovations and highlights opportunities available for the investors including biologic products, diversification of molecular targets, and the shift in regulatory and reimbursement policies. The 88-page report classifies treatment and management of Type 2 diabetes mellitus into insulin-based T2DM therapies and non-insulin based T2DM therapies. The section of the report on T2DM signaling network, disease caution and innovation alignment focuses on the complexity of signaling network and pathways of molecular target integration, besides assessing the first-in-class matrix.
Some of the prominent first-in-class target and pipeline programs evaluated in the report include insulin receptor substrate 1 and insulin receptor substrate 2, G-protein coupled receptor kinase, Type 2 angiotensin II receptor, islet amyloid polypeptide, nacht LRR and PYD domains containing protein, peroxisome proliferate activated receptor gama coactivator 1 alpha (PPARGC1A), glucagon, alpha synuclein, and microtubule associated protein tau. The section on strategic consolidations examines industry-wide first-in-class deals, licensing deals, co-development deals, and first-in-class programs that are not involved in licensing or co-development deals.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org